Ibrutinib Plus Venetoclax for First-Line Treatment of CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial
JAMA Oncol 2021 Jun 10;[EPub Ahead of Print], N Jain, M Keating, P Thompson, A Ferrajoli, JA Burger, G Borthakur, K Takahashi, Z Estrov, K Sasaki, N Fowler, T Kadia, M Konopleva, Y Alvarado, M Yilmaz, C DiNardo, P Bose, M Ohanian, N Pemmaraju, E Jabbour, R Kanagal-Shamanna, K Patel, W Wang, J Jorgensen, SA Wang, N Garg, X Wang, C Wei, N Cruz, A Ayala, W Plunkett, H Kantarjian, V Gandhi, WG WierdaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.